Abstract
In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.
Lingua originale | English |
---|---|
pagine (da-a) | 2408-2412 |
Numero di pagine | 5 |
Rivista | AIDS |
Volume | 24 |
DOI | |
Stato di pubblicazione | Pubblicato - 2010 |
Keywords
- Adult
- Aged
- Drug Interactions
- Female
- HIV Infections
- HIV Protease Inhibitors
- Hodgkin Disease
- Humans
- Male
- Middle Aged
- Ritonavir
- Vinblastine